The way we see it, the impossible is not impossible. It’s simply what hasn’t been achieved yet. For more than 30 years, we’ve pursued it, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases.

Creating Possible drives everything we do. It’s evident in our mission and core values. This is how we built a culture of excellence that is fueled by a passion for improving lives of people around the world.

For us, nothing is impossible – because of the people we work with, the communities we stand with and the partners we push forward with. Our ~12,000 employees band together through science, grit, compassion and courage to prove the impossible wrong.

At Gilead, the tangible results of your contributions are evident. Where every individual matters. Where all employees can enhance their skills through ongoing development. And where we start every day with one question: “What’s next?

Our Purpose
Careers
Careers at Gilead Our Culture Meet Our Employees Inclusion and Diversity in Hiring Compensation, Benefits and Wellbeing Our Global Footprint Early Career Opportunities Hiring Events Talent Community Sign-up
Utility
Privacy Statements Terms Of Use Social Media Guidelines EU Data Disclosure Sitemap
BACK TO MAIN MENU Partnerships and Community COMPASS Initiative HepConnect HIV Age Positively Lift RADIAN TRANScend
BACK TO MAIN MENU Corporate Giving What We Fund Funding Requests Gilead Foundation Gilead Public Health Award
BACK TO MAIN MENU Advancing Global Health COVID-19 HCV Elimination
BACK TO MAIN MENU How We Operate Governance Transparency
BACK TO MAIN MENU Ethics and Code of Conduct Policies Disclosures Anti-Counterfeiting Consumer Product Safety Supplier Information Anti-Bribery and Anti-Corruption Policy Political Contributions
BACK TO MAIN MENU Newsroom Press Releases Media Inquiries
BACK TO MAIN MENU Company Statements Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B) Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19 Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines
We’re exceeding our emission reduction goals and focusing on sustainability at our sites around the world. As we grow, we’ll continue to set the highest possible standards for the buildings we own and build. Read how we’re shrinking our carbon footprint, one step at a time.
Advancing Global Health
We invest in programs that aim to eliminate some of the world’s most challenging public health threats, enable access to medicines and help fight the stigma that prevents people from seeking care.
Sustainability
Partnerships and Community
We're working with organizations around the world to eliminate healthcare inequities and promote social justice. 
Community
Community
Innovation
Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study


Gilead to Present New Data at IAS 2021 Demonstrating the Company’s Commitment to Advancing Innovation in HIV Research